Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

[Short-term safety evaluation of trastuzumab administrated intravenously over 30 minutes with 100 mL saline solution with a focus on infusion reaction].

Hasegawa Y, Miura M, Sato K, Yamanaka Y, Narita J, Shibata S, Suto T.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2545-9. Japanese.

PMID:
24335367
2.

[Adjuvant trastuzumab can be infused safely over 30 minutes].

Abe H, Umeda T, Kawai Y, Tanaka M, Mori T, Cho H, Kubota Y, Mekata E, Kurumi Y, Tani T.

Gan To Kagaku Ryoho. 2010 Oct;37(10):1887-91. Japanese.

PMID:
20948250
3.

Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B.

J Clin Pharmacol. 2013 Feb;53(2):192-201. doi: 10.1177/0091270012436560.

PMID:
23436264
4.

Safety assessment of intravenous administration of trastuzumab in 100ml saline for the treatment of HER2- positive breast cancer patients.

Abe H, Mori T, Kawai Y, Tomida K, Yamazaki K, Kubota Y, Umeda T, Tani T.

Asian Pac J Cancer Prev. 2013;14(8):4843-6.

5.

Infusion of trastuzumab maintenance doses over 30 minutes.

Ring A, Simcock R, Mitra S, Bloomfield D, King J, Simpson S, Sadler G, Webb A.

Ann Oncol. 2008 Aug;19(8):1509-10. doi: 10.1093/annonc/mdn390. Epub 2008 Jun 6. No abstract available.

PMID:
18539615
6.

[An unexpected and severe infusion reaction induced by trastuzumab].

Sacramento Díaz-Carrasco M, Ramírez C, Montenegro S, Alonso-Romero JL.

Farm Hosp. 2014 May 1;38(3):254-5. doi: 10.7399/fh.2014.38.3.1169. Spanish.

7.

Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.

Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN, Barnett CM.

Oncologist. 2014 Mar;19(3):228-34. doi: 10.1634/theoncologist.2013-0286. Epub 2014 Feb 17.

8.

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.

Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, Ozdemir NY, Yazilitas D, Benekli M, Uner A, Yamac D, Demirci U, Yildiz R, Karaca H, Unal OU, Bal O, Gumus M, Buyukberber S; Anatolian Society of Medical Oncology (ASMO).

J Cancer Res Clin Oncol. 2012 Dec;138(12):2145-51. doi: 10.1007/s00432-012-1296-x. Epub 2012 Aug 10.

PMID:
22878681
9.

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P.

J Clin Oncol. 2005 Apr 1;23(10):2162-71.

PMID:
15800309
10.

Nonimmediate hypersensitivity reaction after trastuzumab infusion: a suspected drug-virus interaction.

Ferastraoaru DE, Dickler MN, Patel S, Fischer EA, Pulitzer MP, Myskowski PL, Jerschow E.

J Clin Oncol. 2013 Aug 20;31(24):e407-9. doi: 10.1200/JCO.2012.45.9958. Epub 2013 Jun 10. No abstract available.

PMID:
23752107
11.

The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients.

Yavas O, Yazici M, Eren O, Oyan B.

Swiss Med Wkly. 2007 Oct 6;137(39-40):556-8.

PMID:
17990147
12.

Severe thrombocytopenia related to long-term trastuzumab exposure.

Aguirre E, Taberner T, Luaña A, Morales S, Llombart A.

Tumori. 2013 Jan-Feb;99(1):e1-2. doi: 10.1700/1248.13801.

PMID:
23549016
13.

Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.

[No authors listed]

Prescrire Int. 2015 Apr;24(159):93. No abstract available.

PMID:
25941697
14.

Desensitization to chemotherapeutic agents.

Lieberman P, Castells M.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):116-7. doi: 10.1016/j.jaip.2013.08.013. No abstract available.

PMID:
24565784
15.

Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.

Sawaki M, Ito Y, Tada K, Mizunuma N, Takahashi S, Horikoshi N, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A, Hatake K.

Tumori. 2004 Jan-Feb;90(1):40-3.

PMID:
15143970
16.

Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.

Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M, Scorilas A, Alexopoulos A, Rigatos G.

Onkologie. 2005 Nov;28(11):558-64.

PMID:
16249641
17.

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.

Burris H 3rd, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J.

J Clin Oncol. 2004 May 1;22(9):1621-9.

PMID:
15117984
18.

[Pertuzumab (PERJETA(®) intravenous infusion 420 mg/14 mL): pharmacological properties and clinical development overview].

Myobudani H, Ushiyama N, Ichinose R, Takasuka T.

Nihon Yakurigaku Zasshi. 2014 Feb;143(2):95-102. Review. Japanese. No abstract available.

PMID:
24531903
19.

Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.

Furukawa K, Ito Y, Takahashi S, Sawaki M, Mizunuma N, Horikoshi N, Kasumi F, Akiyama F, Sakamoto G, Furukawa K, Tajiri T, Hatake K.

Breast Cancer. 2006;13(4):329-33.

20.

Ado-trastuzumab emtansine approved for advanced breast cancer.

Traynor K.

Am J Health Syst Pharm. 2013 Apr 1;70(7):562. doi: 10.2146/news130023. No abstract available. Erratum in: Am J Health Syst Pharm. 2013 May 15;70(10):840.

PMID:
23515502

Supplemental Content

Support Center